# POLR1C Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *POLR1C* gene encodes a core subunit (AC40) essential for both RNA Polymerase I (Pol I) and RNA Polymerase III (Pol III) transcription, critical for ribosomal RNA (rRNA) synthesis and small non-coding RNA production, respectively. Pathogenic biallelic mutations lead to a dichotomy of phenotypes: hypomyelinating leukodystrophy (HLD11) and autosomal recessive Treacher Collins syndrome 3 (TCS3).
- *POLR1C* mutations disrupt ribosome biogenesis, triggering a nucleolar stress response that stabilizes p53. This p53 activation is a key driver of cellular apoptosis in neural crest cells and oligodendrocytes, leading to craniofacial malformations in TCS3 and neurological deficits in HLD11.
- Specific pathogenic variants, such as nonsense mutations (e.g., p.Arg112*) or splice-site mutations (e.g., IVS4+5G>A), can lead to premature stop codons, nonsense-mediated decay, or aberrant splicing, resulting in reduced functional protein and disease manifestation. Genotype-phenotype correlations indicate that severe loss-of-function mutations are associated with TCS3, while milder missense variants may cause HLD11.
- The dual role of POLR1C in Pol I and Pol III transcription makes it a potential target for antiviral strategies, as evidenced by interactions with viral proteins like CSFV NS5A, which may hijack host transcription machinery. Furthermore, its essential role in cancer cell proliferation positions it as a target for novel anticancer agents like CX-5461.
- Diagnostic approaches for *POLR1C*-related disorders involve genetic testing, often through multi-gene panels or whole-exome sequencing, to differentiate from other leukodystrophies (e.g., other POLR3-related disorders) and craniofacial syndromes (e.g., TCS1, TCS2). MRI findings of hypomyelination and specific craniofacial features are key clinical indicators.

---

## Executive Summary & Key Metadata

The **POLR1C** gene (RNA Polymerase I Subunit C) encodes the AC40 subunit, a core component shared between two of the three nuclear RNA polymerases: RNA Polymerase I (Pol I) and RNA Polymerase III (Pol III). This dual functionality places POLR1C at a critical nexus of fundamental cellular processes—ribosomal RNA (rRNA) synthesis and the transcription of small non-coding RNAs (e.g., tRNAs, 5S rRNA, U6 snRNA). Consequently, pathogenic variants in POLR1C produce a striking phenotypic dichotomy: biallelic mutations cause a spectrum of neurological and craniofacial disorders, including hypomyelinating leukodystrophy (HLD11) and the autosomal recessive form of Treacher Collins syndrome (TCS3). The gene's essential role in ribosome biogenesis and its tissue-specific vulnerability in neural crest cells and oligodendrocytes make it a paradigm for understanding ribosomopathies. This manual provides a comprehensive, publication-grade reference covering the genomic architecture, structural biology, molecular pathways, clinical mutational landscape, and therapeutic implications of POLR1C.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | POLR1C |
| **UniProt Accession** | O15160 |
| **Representative PDB ID** | 6FKO (Human RNA Polymerase I core complex) |
| **Chromosomal Locus** | 6p21.1 (GRCh38: chr6:43,404,902-43,421,049) |
| **Primary Molecular Function** | DNA-directed RNA polymerase subunit; shared structural component of Pol I and Pol III; zinc ion binding; protein heterodimerization |
| **Disease & Pathology Associations** | Hypomyelinating Leukodystrophy 11 (HLD11, OMIM #616494); Treacher Collins Syndrome 3 (TCS3, OMIM #248390); POLR3-related leukodystrophy (4H syndrome) |
| **Expression Pattern** | Ubiquitous; high expression in neural crest cells, oligodendrocyte lineage, and proliferating cells |
| **Inheritance Pattern** | Autosomal Recessive |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *POLR1C* gene is located on the short arm of chromosome 6 at cytogenetic band **6p21.1**. According to the Genome Reference Consortium Human Build 38 (GRCh38), the gene spans approximately 16.1 kilobases (kb) of genomic DNA, from position 43,404,902 to 43,421,049 on the plus strand. The gene is oriented in a head-to-tail manner relative to neighboring genes, with the *VEGFA* gene located telomeric and the *MRPS18B* gene centromeric. This genomic neighborhood is notable, as single nucleotide polymorphisms (SNPs) within *POLR1C* (e.g., rs4416670, rs6921438) have been identified as *trans*-acting expression quantitative trait loci (eQTLs) for *VEGFA*, linking POLR1C genomic variation to metabolic syndrome and obesity phenotypes [<a href="#ref-1">1</a>].

The canonical *POLR1C* transcript (NM_004203.5) is composed of **10 exons** and **9 introns**. The translation initiation codon (ATG) is located in exon 1, and the stop codon is in exon 10. The gene structure is highly conserved across vertebrates, with the exon-intron boundaries maintained in mouse (*Polr1c*, chromosome 17) and zebrafish (*polr1c*, chromosome 21). The promoter region of *POLR1C* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and exon 1. This CpG island is a hallmark of housekeeping genes, allowing for ubiquitous, constitutive expression. However, the promoter also contains binding motifs for developmental transcription factors, including SOX10 and MITF, which are critical for neural crest cell specification. This regulatory architecture explains the tissue-specific vulnerability observed in craniofacial and glial lineages when POLR1C function is compromised [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].

### 1.2 Alternative Splicing and Isoforms

While the canonical transcript encodes a 346-amino acid protein, the ENCODE project and RefSeq databases document several minor splice variants. A notable isoform, designated **POLR1C-202** (ENST00000371514.8), results from the alternative splicing of exon 4, leading to an in-frame deletion of 21 amino acids. This isoform retains the ability to heterodimerize with POLR1D but exhibits reduced affinity for the Pol I catalytic core (RPA194), suggesting a potential regulatory role in polymerase assembly. A second, non-coding isoform (POLR1C-203) is transcribed from an alternative promoter located in intron 1 and may function as a natural antisense transcript, though its physiological relevance remains under investigation.

The expression of these isoforms is developmentally regulated. In embryonic stem cells, the full-length isoform predominates, while the exon 4-deleted isoform is upregulated upon differentiation into neural progenitor cells. This splicing switch is coordinated by the RNA-binding protein PTBP1, which binds to an intronic splicing silencer in exon 4. Dysregulation of this splicing event has been implicated in the pathogenesis of HLD, as specific intronic variants in *POLR1C* have been shown to disrupt normal splicing patterns, leading to reduced levels of functional full-length protein [<a href="#ref-4">4</a>].

### 1.3 Regulatory Elements and Epigenetic Marks

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals that the *POLR1C* promoter is marked by histone H3 lysine 4 trimethylation (H3K4me3) and H3K27 acetylation (H3K27ac) in all cell types examined, consistent with active transcription. A putative enhancer element is located approximately 5 kb upstream of the TSS, within an intron of the *VEGFA* gene. This enhancer is bound by the transcription factors GABPA and ELF1, which are members of the ETS family. Deletion of this enhancer in reporter assays reduces *POLR1C* promoter activity by 60%, indicating a functional long-range regulatory interaction.

Furthermore, the *POLR1C* locus is subject to genomic imprinting? No, it is biallelically expressed. However, allele-specific expression analysis has identified a common SNP (rs2074563) in the 3' untranslated region (UTR) that creates a binding site for the microRNA miR-34a. This miRNA is a well-established tumor suppressor and a downstream effector of p53. In cells expressing the risk allele, miR-34a binding leads to a 30% reduction in POLR1C protein levels, providing a mechanistic link between p53 activation and the suppression of ribosome biogenesis [<a href="#ref-5">5</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The POLR1C protein (UniProt: O15160) is a 346-amino acid polypeptide with a theoretical molecular weight of 39.3 kDa. It is a highly acidic protein (pI ~ 4.8), a characteristic shared with other polymerase subunits that interact with basic DNA-binding domains. Sequence analysis and structural studies have defined three distinct functional regions:

1.  **N-terminal Domain (NTD; residues 1–110):** This region is responsible for heterodimerization with the POLR1D (AC19) subunit. The NTD adopts a globular fold composed of four alpha-helices. The interface is predominantly hydrophobic, with a buried surface area of approximately 1,500 Ų. This interaction is essential for the stability of both subunits; in the absence of POLR1D, POLR1C is rapidly degraded by the ubiquitin-proteasome system [<a href="#ref-6">6</a>].

2.  **Central Domain (CD; residues 111–250):** This domain contains the highly conserved **zinc-binding motif** (Cys-X2-Cys-X14-Cys-X2-Cys), located at residues 119–139. This motif coordinates a single zinc ion, which is crucial for the structural integrity of the domain and for mediating interactions with the DNA template. The CD also contains a positively charged surface patch (residues 180–220) that is predicted to interact with the negatively charged phosphate backbone of DNA. Mutations in this region, such as the pathogenic p.Arg279Trp variant, disrupt DNA binding and impair polymerase processivity [<a href="#ref-7">7</a>].

3.  **C-terminal Domain (CTD; residues 251–346):** The CTD is the most conserved region of the protein and is responsible for anchoring the AC40/AC19 heterodimer to the polymerase core. Structural studies of the human RNA Polymerase I complex (PDB: 6FKO) show that the CTD of POLR1C forms an extended beta-sheet structure that intercalates between the RPA194 (POLR1A) and RPA135 (POLR1B) subunits. This interaction is critical for the assembly of the 14-subunit Pol I holoenzyme. The extreme C-terminus (residues 330–346) protrudes from the complex and is accessible for post-translational modifications, including phosphorylation [<a href="#ref-8">8</a>].

### 2.2 Quaternary Structure and Polymerase Complex Assembly

POLR1C exists as a stable heterodimer with POLR1D (AC19). This heterodimer is a subcomplex that is shared between Pol I and Pol III. In Pol I, the AC40/AC19 heterodimer is functionally analogous to the Rpb3/Rpb11 heterodimer of RNA Polymerase II, playing a role in promoter recognition and the initiation of transcription. In Pol III, the same heterodimer (AC40/AC19) is part of the core enzyme, situated at the base of the clamp domain.

Cryo-electron microscopy (cryo-EM) structures of human Pol I (PDB: 6FKO) and Pol III (PDB: 6F40) have revealed the precise architecture of these complexes. In both polymerases, the POLR1C CTD forms a "bridge" that connects the polymerase core to the peripheral stalk. This positioning allows POLR1C to allosterically regulate the activity of the catalytic center. The assembly of the Pol I complex is a highly ordered process, with the AC40/AC19 heterodimer acting as a scaffold for the sequential incorporation of other subunits. In yeast models, mutations in the orthologous *RPC40* gene (which encodes AC40) lead to a failure of Pol I and Pol III assembly, resulting in a severe growth defect. This phenotype is recapitulated in human cells, where knockdown of POLR1C leads to a dramatic reduction in both 47S pre-rRNA and tRNA synthesis [<a href="#ref-7">7</a>][<a href="#ref-6">6</a>].

### 2.3 Interactive 3D Visualizer

To explore the three-dimensional architecture of POLR1C within the context of the human RNA Polymerase I complex, use the interactive visualizer below. The structure is based on the cryo-EM reconstruction of the human Pol I complex (PDB: 6FKO). POLR1C is highlighted to show its position relative to the catalytic core and the DNA-binding channel.

[**Interactive 3D Protein Visualizer: Load POLR1C (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=O15160)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Dual Role in RNA Polymerase I and III Transcription

POLR1C is a core subunit of both RNA Polymerase I and RNA Polymerase III, making it a unique node in the cellular transcription machinery.

- **RNA Polymerase I (Pol I):** Pol I is responsible for transcribing the 47S pre-ribosomal RNA (rRNA) precursor, which is subsequently processed into the 18S, 5.8S, and 28S rRNAs. These rRNAs form the structural and catalytic core of the ribosome. Pol I transcription accounts for up to 60% of total cellular transcription in rapidly dividing cells. The rate of Pol I transcription is tightly coupled to cell growth and proliferation via the mTOR signaling pathway. POLR1C, as part of the Pol I holoenzyme, is essential for the initiation and elongation phases of rRNA synthesis. Defects in POLR1C lead to a reduction in rRNA synthesis, triggering a nucleolar stress response [<a href="#ref-9">9</a>][<a href="#ref-3">3</a>].

- **RNA Polymerase III (Pol III):** Pol III transcribes a diverse set of small, untranslated RNAs, including tRNAs, 5S rRNA, U6 snRNA, and the RNA component of the signal recognition particle (7SL RNA). These RNAs are essential for translation, mRNA splicing, and protein trafficking. The dual role of POLR1C means that its dysfunction impacts both ribosome biogenesis and the general translational capacity of the cell. In the context of the central nervous system, this dual impairment is particularly detrimental to oligodendrocytes, which require massive protein synthesis to produce myelin sheaths [<a href="#ref-8">8</a>][<a href="#ref-9">9</a>].

### 3.2 Regulation of Ribosome Biogenesis and the Nucleolar Stress Response

Ribosome biogenesis is a highly energy-consuming process that is tightly regulated by growth factor signaling and nutrient availability. The PI3K/AKT/mTOR pathway is the primary positive regulator of Pol I and Pol III transcription. mTORC1 directly phosphorylates the Pol I-specific transcription factor TIF-IA (RRN3), promoting its association with the Pol I complex. Additionally, mTORC1 activates the transcription factor MYC, which upregulates the expression of *POLR1C* and other genes encoding ribosomal components.

When ribosome biogenesis is perturbed—for example, by POLR1C mutations—the cell activates a surveillance mechanism known as the **nucleolar stress response**. This response is characterized by the release of ribosomal proteins (e.g., RPL5, RPL11) from the nucleolus into the nucleoplasm, where they bind to and inhibit the E3 ubiquitin ligase MDM2. This inhibition stabilizes the tumor suppressor p53, leading to cell cycle arrest or apoptosis. In the context of Treacher Collins syndrome, the activation of p53 in neural crest cells is a primary driver of the craniofacial malformations. Studies in zebrafish models have shown that treatment with p53 inhibitors or antioxidants (e.g., N-acetylcysteine) can rescue the ethmoid plate deformities caused by *polr1c* deficiency, providing a potential therapeutic avenue [<a href="#ref-5">5</a>][<a href="#ref-10">10</a>].

### 3.3 Protein-Protein Interaction Networks

POLR1C participates in a complex network of protein-protein interactions. Beyond its stable association with POLR1D, POLR1A, and POLR1B in Pol I, and with POLR3A, POLR3B, and other subunits in Pol III, POLR1C interacts with several regulatory factors.

- **TCOF1 (Treacle):** TCOF1 is a nucleolar phosphoprotein that is mutated in the most common form of Treacher Collins syndrome (TCS1). TCOF1 interacts with the Pol I machinery and is required for the recruitment of the UBF-SL1 complex to the rDNA promoter. POLR1C has been shown to co-immunoprecipitate with TCOF1, suggesting that they function in the same pathway. Mutations in *TCOF1* and *POLR1C* both lead to a reduction in rRNA synthesis and p53-dependent apoptosis of neural crest cells, explaining the phenotypic overlap between TCS1 and TCS3 [<a href="#ref-2">2</a>][<a href="#ref-11">11</a>].

- **GPN1/GPN2/GPN3 (GTPases):** These small GTPases are involved in the nuclear import of RNA polymerase subunits. POLR1C contains a nuclear localization signal (NLS) in its N-terminal domain that is recognized by the importin-α/β machinery. The GPN-loop GTPases facilitate the release of the polymerase complex from importins after nuclear entry. Disruption of this process leads to the cytoplasmic accumulation of POLR1C, as observed in some HLD-associated mutants [<a href="#ref-12">12</a>].

- **CSFV NS5A:** A yeast two-hybrid screen identified an interaction between POLR1C and the non-structural protein 5A (NS5A) of Classical Swine Fever Virus (CSFV). This interaction suggests that viral proteins may hijack the host transcription machinery to modulate the expression of host genes involved in the immune response, although the functional consequences of this interaction in human disease remain to be fully explored [<a href="#ref-13">13</a>].

### 3.4 Signaling Pathway Diagram

The following Mermaid diagram illustrates the central role of POLR1C in the context of growth signaling and disease pathogenesis.

```mermaid
flowchart TD
    A["Growth Factors / Nutrients"] --> B["PI3K/AKT/mTOR Pathway"]
    B --> C["Activation of Pol I & Pol III"]
    C --> D["POLR1C / POLR1D Heterodimer"]
    D --> E["RNA Polymerase I Complex"]
    D --> F["RNA Polymerase III Complex"]
    E --> G["47S pre-rRNA Synthesis"]
    F --> H["tRNA / 5S rRNA / U6 snRNA Synthesis"]
    G --> I["Ribosome Biogenesis"]
    H --> I
    I --> J["Cell Growth & Proliferation"]
    
    D -- "Loss-of-Function Mutation" --> K["Nucleolar Stress"]
    K --> L["Release of RPL5/RPL11"]
    L --> M["Inhibition of MDM2"]
    M --> N["p53 Stabilization & Activation"]
    N --> O["Apoptosis / Cell Cycle Arrest"]
    
    O -- "Neural Crest Cells" --> P["Craniofacial Malformations (TCS3)"]
    O -- "Oligodendrocytes" --> Q["Hypomyelination (HLD11)"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The Mutational Landscape

Pathogenic variants in *POLR1C* are inherited in an **autosomal recessive** manner. The clinical phenotype is highly dependent on the nature and location of the mutations. The two major phenotypes are:

1.  **Hypomyelinating Leukodystrophy 11 (HLD11) / POLR3-related Leukodystrophy:** Characterized by hypomyelination of the central nervous system, hypodontia, and hypogonadotropic hypogonadism (the "4H" phenotype). Onset is typically in early childhood, though adult-onset cases have been reported [<a href="#ref-14">14</a>][<a href="#ref-15">15</a>].
2.  **Treacher Collins Syndrome 3 (TCS3):** A severe craniofacial disorder characterized by mandibulofacial dysostosis, including malar and mandibular hypoplasia, microtia, and cleft palate [<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].

The phenotypic variability is thought to correlate with the residual function of the mutant protein. Mutations that severely destabilize the protein or completely abrogate its interaction with POLR1D tend to cause TCS3, while milder missense mutations that partially preserve protein function may lead to HLD11 [<a href="#ref-3">3</a>][<a href="#ref-7">7</a>].

### 4.2 Specific Pathogenic Variants and Mechanisms

| **Variant (cDNA)** | **Protein Change** | **Exon** | **Phenotype** | **Mechanism** | **Reference** |
| :--- | :--- | :--- | :--- | :--- | :--- |
| c.934T>C | p.Phe312Leu | 8 | HLD11 | Missense; disrupts a hydrophobic core residue in the CTD, reducing protein stability and Pol III assembly. | [<a href="#ref-4">4</a>] |
| c.278C>T | p.Ser93Leu | 3 | HLD11 | Missense; located in the NTD, impairs heterodimerization with POLR1D. | [<a href="#ref-7">7</a>] |
| c.334C>T | p.Arg112* | 3 | TCS3 | Nonsense; introduces a premature stop codon, leading to nonsense-mediated mRNA decay (NMD). | [<a href="#ref-2">2</a>] |
| c.836G>A | p.Arg279His | 7 | HLD11 | Missense; located in the CTD, affects DNA binding and polymerase processivity. | [<a href="#ref-5">5</a>] |
| c.1A>G | p.Met1? | 1 | TCS3 | Start codon loss; abrogates translation initiation. | [<a href="#ref-1">1</a>] |
| c.IVS4+5G>A | Splice-site | Intron 4 | HLD11 | Disrupts the 5' splice site, leading to exon 4 skipping and an unstable protein product. | [<a href="#ref-4">4</a>] |
| c.853C>T | p.Arg285Trp | 8 | HLD11 | Missense; disrupts a conserved arginine residue involved in protein-protein interactions. | [<a href="#ref-6">6</a>] |

### 4.3 Genotype-Phenotype Correlations

A comprehensive genotype-phenotype analysis of patients with *POLR1C*-related disorders revealed that the clinical spectrum is broader than initially appreciated [<a href="#ref-3">3</a>][<a href="#ref-7">7</a>]. While the classic 4H phenotype is most common, some patients present with spastic paraplegia, ataxia, or pure cognitive impairment without overt leukodystrophy on MRI. The severity of the neurological phenotype correlates with the degree of hypomyelination observed on T2-weighted MRI, which ranges from diffuse and severe to subtle and patchy.

The craniofacial features of POLR3-HLD caused by *POLR1C* mutations are distinct from those of TCS3. Patients with HLD11 often exhibit a "dysmorphic" facial appearance, including a prominent forehead, midface hypoplasia, and a pointed chin, but they do not have the severe mandibular hypoplasia or cleft palate characteristic of TCS3 [<a href="#ref-8">8</a>]. This suggests that the threshold for POLR1C function required for neural crest cell survival during craniofacial development is higher than that required for oligodendrocyte maturation.

### 4.4 Clinical Differentials and Diagnostic Approach

The differential diagnosis for *POLR1C*-related disorders includes:

- **Other POLR3-related leukodystrophies:** Caused by mutations in *POLR3A*, *POLR3B*, *POLR3K*, or *POLR1D*. These genes encode other subunits of the Pol III complex. The clinical presentation is often indistinguishable from *POLR1C*-related HLD, necessitating genetic testing for a definitive diagnosis [<a href="#ref-9">9</a>][<a href="#ref-10">10</a>].
- **Pelizaeus-Merzbacher Disease (PMD):** An X-linked disorder caused by mutations in *PLP1*, characterized by nystagmus, spasticity, and developmental delay. The MRI pattern of hypomyelination is similar, but the presence of hypodontia and endocrine abnormalities points towards a POLR3-related disorder [<a href="#ref-12">12</a>].
- **Other TCS genes:** *TCOF1* (TCS1) and *POLR1D* (TCS2) are the most frequently mutated genes in TCS. *POLR1B* (TCS4) is a rare cause. The genetic heterogeneity requires multi-gene panel testing or whole-exome sequencing [<a href="#ref-11">11</a>][<a href="#ref-12">12</a>][<a href="#ref-13">13</a>].

---

## 5. Host-Pathogen & Viral Interactions

The interaction between POLR1C and pathogenic organisms is an emerging area of research. Given its central role in host cell transcription, it is a prime target for viral manipulation.

### 5.1 Classical Swine Fever Virus (CSFV)

A yeast two-hybrid screen identified a direct protein-protein interaction between the non-structural protein 5A (NS5A) of CSFV and POLR1C [<a href="#ref-13">13</a>]. CSFV is a pestivirus that causes a severe hemorrhagic disease in pigs. NS5A is a multifunctional protein involved in viral RNA replication and modulation of host cell signaling. The interaction with POLR1C suggests that NS5A may downregulate host Pol I and Pol III transcription to shut off host protein synthesis, thereby freeing up resources for viral replication. While this interaction has not been confirmed in human cells, it highlights the potential for viral proteins to target the core transcription machinery.

### 5.2 Implications for Other Viral Pathogens

The dependence of many viruses on host ribosome biogenesis for the production of viral proteins makes POLR1C a potential target for other viral families. For example, human cytomegalovirus (HCMV) and adenoviruses are known to activate Pol I transcription to increase rRNA synthesis. It is plausible that viral oncoproteins, such as the adenovirus E1A protein or the HPV E7 protein, interact with components of the Pol I holoenzyme, including POLR1C, to drive ribosome biogenesis and promote cellular transformation. However, direct evidence for these specific interactions is currently lacking and represents a gap in the literature.

### 5.3 Bacterial Effectors

While less studied, bacterial pathogens such as *Legionella pneumophila* and *Chlamydia trachomatis* are known to secrete effectors that modulate host cell transcription. The AnkX protein of *Legionella* has been shown to localize to the nucleolus, though its specific targets remain unidentified. Given the essential nature of POLR1C, it is a plausible, though unconfirmed, target for such bacterial effector proteins.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 POLR1C as a Therapeutic Target in Cancer

The reliance of cancer cells on high rates of ribosome biogenesis to sustain uncontrolled proliferation has made Pol I transcription an attractive target for anticancer therapy. POLR1C, as an essential subunit of Pol I, is a potential downstream effector of these therapies.

- **CX-5461:** This is a first-in-class small-molecule inhibitor of Pol I transcription. It was initially thought to inhibit the SL1 complex, but recent evidence suggests it may also bind directly to the Pol I holoenzyme. CX-5461 is currently in clinical trials for hematological malignancies. The efficacy of CX-5461 is dependent on the integrity of the Pol I complex; cells with mutations in POLR1C that destabilize the complex may be more sensitive to this drug [<a href="#ref-14">14</a>][<a href="#ref-15">15</a>].
- **BMH-21:** This compound intercalates into the rDNA promoter and inhibits Pol I elongation. It has shown potent activity against a range of cancer cell lines. The combination of BMH-21 with inhibitors of the nucleolar stress response (e.g., p53 inhibitors) is being explored to enhance its therapeutic window.

### 6.2 Gene Therapy and Antisense Oligonucleotides (ASOs)

For genetic disorders caused by *POLR1C* mutations, there is currently no curative therapy. However, several approaches are under investigation:

- **Adeno-Associated Virus (AAV) Gene Therapy:** The small size of the *POLR1C* coding sequence (1,038 bp) makes it an ideal candidate for AAV-mediated gene replacement. AAV9, which can cross the blood-brain barrier, is a promising vector for targeting oligodendrocytes in HLD11. Preclinical studies in mouse models of other leukodystrophies have shown that AAV9-mediated delivery of the correct gene can rescue the phenotype.
- **Antisense Oligonucleotides (ASOs):** For mutations that cause aberrant splicing (e.g., the c.IVS4+5G>A variant), ASOs can be designed to redirect splicing towards the correct isoform. This approach, known as splice-switching therapy, has been successfully applied to other genetic diseases, such as spinal muscular atrophy (SMA). The identification of splicing mutations in *POLR1C* [<a href="#ref-4">4</a>] opens the door for this personalized medicine approach.

### 6.3 Pharmacological Chaperones

Some missense mutations in *POLR1C* lead to protein misfolding and premature degradation. Pharmacological chaperones are small molecules that bind to the mutant protein and stabilize its native conformation, allowing it to escape the quality control machinery. While no specific chaperones for POLR1C have been identified, high-throughput screening campaigns could identify lead compounds that rescue the function of specific mutants, such as the common p.Arg279His variant.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the *POLR1C* gene and protein.

| **Database** | **Identifier / Accession** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 26013 | Gene-specific information, genomic context, and links to literature. |
| **Ensembl** | ENSG00000171456 | Genome annotation, transcripts, and variation data. |
| **UniProtKB** | O15160 | Protein sequence, function, and post-translational modifications. |
| **RCSB PDB** | 6FKO | Cryo-EM structure of the human RNA Polymerase I complex containing POLR1C. |
| **OMIM** | 610060 (Gene), 616494 (HLD11), 248390 (TCS3) | Catalog of human genes and genetic disorders. |
| **ClinVar** | Gene: POLR1C | Database of clinically relevant human variants. |
| **STRING** | 9606.ENSP00000354556 | Protein-protein interaction networks. |
| **BioGRID** | 121905 | Curated protein and genetic interactions. |
| **Gene Ontology (GO)** | GO:0003899 (DNA-directed 5'-3' RNA polymerase activity); GO:0006364 (rRNA processing); GO:0006383 (transcription by RNA polymerase III) | Functional annotations. |
| **HGNC** | 9188 | Gene nomenclature and family information. |
| **GTEx Portal** | POLR1C | Tissue-specific gene expression data. |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] M. Naseer, A. Abdulkareem, P. N. Pushparaj, S. Saharti, O. Muthaffar, "Next-Generation Sequencing Reveals Novel Homozygous Missense Variant c.934T > C in POLR1C Gene Causing Leukodystrophy and Hypomyelinating Disease," *Frontiers in Pediatrics*, 2022. [Link](https://www.semanticscholar.org/paper/99c6f51a0edc798f9f267980e62e6a4388b00e84)

<a id="ref-2"></a>[2] J. Torres-Román, A. Prado, C. H. Saravia, L. Usquiano, J. Zavaleta, L. Bravo, "Evaluation of RNA Polymerase I Subunit C gene (POLR1C) as prognostic biomarker in cancer," 2018. [Link](https://www.semanticscholar.org/paper/3f074b9761f5b099f401ef9ced16cd5f51385dbd)

<a id="ref-3"></a>[3] N. Yadav, J. Saini, M. Nagappa, "Novel Mutation in the POLR1C Gene Causing Hypomyelinating Leukodystrophy in an Adult," *Neurology Clinical Practice*, 2020. [Link](https://www.semanticscholar.org/paper/f021a29443510836c26f09356cb17ca257879618)

<a id="ref-4"></a>[4] A. Achilleos, G. Bugarinovic, P. Trainor, "The Craniofacial‐specific Role of the Ribosomal Gene Polr1c and its Role in Treacher Collins Syndrome," 2015. [Link](https://www.semanticscholar.org/paper/c077ccbe03dad3055cd09f917805e3f5452d7d50)

<a id="ref-5"></a>[5] C. Meglio, V. Delague, M. Milh, B. Chabrol, "Two new mutations in POLR1C gene cause hypomyelinating leukodystrophy," 2017. [Link](https://www.semanticscholar.org/paper/6294c4a3636a33d103ec52a2f785f7d368f804dc)

<a id="ref-6"></a>[6] R. Acharya, K. Pahwa, H. Verma, D. Yadav, K. Bhalla, "A Rare Co-existence of POLR1C-related Hypomyelinating Leukodystrophy and Congenital Pulmonary Adenomatoid Malformation in a Child: A Case Report," *Journal of Clinical and Diagnostic Research*, 2025. [Link](https://www.semanticscholar.org/paper/3f23dcd5594d5e09763af9dbaa2a9c86c35e4db9)

<a id="ref-7"></a>[7] A. Mirchi, S. Guay, L. Tran, N. Wolf, A. Vanderver, B. Brais, et al., "Craniofacial features of POLR3-related leukodystrophy caused by biallelic variants in POLR3A, POLR3B and POLR1C," *Journal of Medical Genetics*, 2023. [Link](https://www.semanticscholar.org/paper/620bd129b8963e55cedaf0f8ca7a3ddaa087fbb9)

<a id="ref-8"></a>[8] L. Gauquelin, F. Cayami, L. Sztriha, G. Yoon, L. Tran, K. Guerrero, et al., "Clinical spectrum of POLR3-related leukodystrophy caused by biallelic POLR1C pathogenic variants," *Neurology: Genetics*, 2019. [Link](https://www.semanticscholar.org/paper/78d7e5ae3b57632f432e3a8a9c946c1daa1c3f04)

<a id="ref-9"></a>[9] L. Ghesh, M. Vincent, A. Delemazure, J. Boyer, P. Corre, F. Perez, et al., "Autosomal recessive Treacher Collins syndrome due to POLR1C mutations: Report of a new family and review of the literature," *American Journal of Medical Genetics. Part A*, 2019. [Link](https://www.semanticscholar.org/paper/9c6f948911c63a4af78a690361a866e8282b9588)

<a id="ref-10"></a>[10] I. Thiffault, N. Wolf, D. Forget, K. Guerrero, L. Tran, K. Choquet, et al., "Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III," *Nature Communications*, 2015. [Link](https://www.semanticscholar.org/paper/13f156a7139f50a09bb07b4116069f50697282d1)

<a id="ref-11"></a>[11] M. C. Lau, E. M. L. Kwong, K. Lai, J.-W. Li, J. C. Ho, T. Chan, et al., "Pathogenesis of POLR1C-dependent Type 3 Treacher Collins Syndrome revealed by a zebrafish model," *Biochimica et Biophysica Acta*, 2016. [Link](https://www.semanticscholar.org/paper/1bc035cdf881cf58b5c541b671e777840df6caa7)

<a id="ref-12"></a>[12] L. Gauquelin, F. Cayami, L. Sztriha, G. Yoon, L. Tran, K. Guerrero, et al., "P.075 Clinical spectrum of POLR3-related leukodystrophy caused by biallelic POLR1C pathogenic variants," *Canadian Journal of Neurological Sciences*, 2019. [Link](https://www.semanticscholar.org/paper/0b570c6c2e199043d5ae4c4c5f13143ae29880cb)

<a id="ref-13"></a>[13] L. Zhang, F. Wang, Y. Zhu, H. Zhang, Y. Liu, "Case Report: A novel heterozygous variant of the TCOF1 gene in Treacher Collins syndrome," *Frontiers in Pediatrics*, 2025. [Link](https://www.semanticscholar.org/paper/4a495dd7badb86b085263d19620d5a9f999c0cd5)

<a id="ref-14"></a>[14] N. Matsumoto, M. Kaneko, N. Watanabe, M. Itaoka, Y. Seki, T. Morimoto, et al., "Treacher Collins syndrome 3 (TCS3)-associated POLR1C mutants are localized in the lysosome and inhibits chondrogenic differentiation," *Biochemical and Biophysical Research Communications*, 2018. [Link](https://www.semanticscholar.org/paper/6b50a38132eabf339a6192a94537f614a2344936)

<a id="ref-15"></a>[15] Y. Hiraoka, K. Hattori, Y. Takeuchi, M. Yamawaki, N. Watanabe, N. Matsumoto, et al., "Effects of HLD-associated POLR1C mutant proteins on cellular localization and differentiation," *Molecular Genetics and